Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

60
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
60
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

60
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
60
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

50
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
50
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

257
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
257
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

43
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
43
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

96
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PCSK9 Inhibitors in Heart Transplant Recipients.

Transplantation proceedings·2026
Same author

Clinical Phenotypes in Heart Transplantation: Implications for Prognosis and Personalized Follow-up.

Transplantation·2026
Same author

Evaluation of IVIG for Prevention of Infections Occurring On-study and Treatment of Infection of Solid Organ Recipients With Secondary Antibody Deficiency: A Phase 2 Randomized Clinical Trial.

Transplantation direct·2026
Same author

Serological protection against influenza and cardiovascular events in cardiac ICU patients during seasonal epidemics.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

The role of the bone morphogenetic protein receptor 2 pathway in group 2 pulmonary hypertension secondary to valvular heart disease.

ERJ open research·2025
Same author

Dissociated rhythms in a heart transplant with two left atrial appendages.

European heart journal·2025

Related Experiment Video

Updated: Oct 8, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K

Continuous-flow left ventricular assist device: Current knowledge, complications, and future directions.

Javier Castrodeza1,2, Carlos Ortiz-Bautista3,4, Francisco Fernández-Avilés3,4,5

  • 1Cardiology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain. jcastrodeza5@gmail.com.

Cardiology Journal
|December 30, 2021
PubMed
Summary

New continuous-flow left ventricular assist devices offer a promising alternative to heart transplantation for advanced heart failure, with improved survival rates. Understanding these devices, their complications, and recent advances is crucial for clinicians.

Keywords:
continuous flowleft ventricular assist devicemechanical circulatory support

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Related Experiment Videos

Last Updated: Oct 8, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

2.0K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.8K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Biomedical Engineering

Background:

  • Advanced heart failure necessitates innovative therapeutic strategies beyond traditional heart transplantation.
  • Continuous-flow left ventricular assist devices (CF-LVADs) represent a significant advancement in mechanical circulatory support.
  • New-generation CF-LVADs demonstrate improved outcomes, making them a viable alternative to transplantation.

Purpose of the Study:

  • To provide a comprehensive overview of current knowledge regarding CF-LVADs.
  • To detail the management strategies for potential complications associated with CF-LVAD therapy.
  • To discuss future directions and advancements in CF-LVAD technology for heart failure treatment.

Main Methods:

  • Literature review of recent studies and clinical trials on CF-LVADs.
  • Analysis of complication rates and management protocols.
  • Synthesis of expert opinions and emerging trends in the field.

Main Results:

  • New-generation CF-LVADs achieve promising 2-year event-free survival rates.
  • Widespread global adoption necessitates familiarity with CF-LVAD fundamentals and complications.
  • Effective management of complications is key to successful long-term support.

Conclusions:

  • CF-LVADs are a crucial therapeutic option for advanced heart failure, rivaling transplantation.
  • Continuous learning and adaptation to technological advances are essential for healthcare providers.
  • Future research should focus on further improving device longevity and patient quality of life.